Skip to content 
Technology goes global, strong partnerships continue. Jiangbei has more good news. Recently, Shengxin Pharmaceutical’s self-developed dual-specific antibody SIM0709 has completed its “global entry” – the company has reached an authorization cooperation agreement with global pharmaceutical giant Boeringer Ingelheim, and will jointly develop innovative therapies for inflammatory bowel disease.
According to the agreement, Boeringer Ingelheim obtains the global rights of SIM0709 outside the Greater China region. Shengxin Pharmaceutical will receive an upfront payment and, based on subsequent development, registration and sales progress, will receive a maximum payment of 1.058 billion euros (over 8 billion yuan). Notably, the production of this innovative drug will also be located in the new area in the future.
01
Why is one authorization worth over 8 billion yuan? The answer lies in the drug itself.
Currently, inflammatory bowel disease affects over 3 million people worldwide. This is a lifelong and progressive disease that leads to frequent hospitalizations, surgeries, and severely impacts the quality of life. Even though many people are using existing anti-inflammatory treatments, they still cannot reverse the disease and may even experience serious complications.
Patients are waiting for more effective treatments, and the birth of new drugs is naturally of great concern.
“SIM0709 was developed by Sunwin Pharmaceutical’s multi-antibody technology platform and has the potential to be a ‘first-in-class’ product in the treatment of inflammatory bowel disease.” Zhou Gaobo, the chief investment officer of Sunwin Pharmaceutical, introduced that this is a bispecific antibody that can simultaneously target the two “main culprits” causing inflammatory bowel disease – tumor necrosis factor-like cytokine 1A and interleukin 23, blocking the pathways of disease occurrence and development.
Such great potential and prospects have become the key to attracting global attention. As a global leader in the treatment of immunology and respiratory system diseases, Boehringer Ingelheim was precisely attracted by the innovative value of SIM0709 and thus came forward to purchase the innovation at a high price.
In the future, through cooperation, the two enterprises will “join forces” in terms of innovative research and development capabilities and global development and commercialization advantages, working together and efficiently advancing clinical development. This also means that many patients who have long suffered from abdominal pain, diarrhea, and even repeated hospitalizations and surgeries now have new expectations.
02
Behind this single license agreement lies technical strength.
In fact, this is not the first time that XianSheng Pharmaceutical has ventured into overseas technology markets. Previously, the company has reached licensing agreements with a number of major pharmaceutical giants such as AbbVie in the US, Ipsen in France, and NextCure in the US.
As of now, XianSheng Pharmaceutical has 5 self-developed innovative drug early-stage research projects that have achieved external technology licensing. The cumulative potential transaction amount has exceeded 4.6 billion US dollars. The funds obtained will be used to continue research and development, promote the establishment of more innovative projects, accelerate the launch of clinical studies in China and overseas, and keep the innovation engine running.
Of course, the dazzling technological strength on the international stage requires even stronger support behind it. For instance, in the five projects where Shengsheng Pharmaceutical completed the process of going global, the drugs used in the early clinical trials conducted in Europe and America were all produced by “Antibody Factory” Shengsheng Biotechnology located in the New District’s Pharmaceutical Valley.
Currently, this “super factory” is launching a new capacity expansion at its original site. Once completed, it will achieve an annual production capacity of 100,000 liters of raw liquid and 6 million doses of injection preparations, further supporting Shengsheng Pharmaceutical’s development and production of innovative antibody drugs.
The overseas expansion of Xian Sheng Pharmaceutical is not an isolated case.
In recent years, the life health industry in the new district has been booming. Under Long Wangshan Mountain, the story of “innovation in the new district and global orders” is being repeated one after another: Vistintibao and Dianthus Therapeutics have reached a sole global partnership, with a total transaction amount of up to 1 billion US dollars; Ye Jie Kang’an and Neurocrine Biosciences have reached a project cooperation, with a total potential value of 881.5 million US dollars… And these innovative drugs that have achieved “technology monetization” are all genuine first-of-their-kind and best-of-the-best in the same category.
Focusing on innovation and continuously expanding into the global market, we look forward to more innovative drugs benefiting patients traveling from Jiangbei to the world.
